Professor Caroline Ford

Back to

Professor Caroline Ford leads the Gynaecological Cancer Research Group (GCRG) at the University of New South Wales. She established her laboratory at the Lowy Cancer Research Group in 2010 after international postdoctoral fellowships at the University of Toronto, Canada and Lund University, Sweden. She has successfully led her research group for over 13 years maintaining consistent competitive research funding and collaborating closely with clinicians and women with gynaecological cancers.

The Gynaecological Cancer Research Group (GCRG) aims to understand why gynaecological cancers develop, how and why they spread throughout the body, and how best to treat them. “Gynaecological cancer” encompasses all cancers of the female reproductive system, though current research focuses on ovarian and endometrial cancer. The GCRG works closely with clinical staff at the Royal Hospital for Women, Sydney and has a number of studies involving biospecimen collection (tissue, blood and ascites) from women with gynaecological cancer. Major projects include the development of an early detection test for ovarian cancer, and the identification of key targets for anti-metastatic therapies in ovarian and endometrial cancer. The GCRG is also actively investigating biological properties of ovarian cancer-associated ascites, and further developing innovative in vitro organotypic model of ovarian and endometrial cancer for pre-clinical drug testing. They also investigate cell-free DNA and its fluctuation in women, particularly in benign gynaecological diseases including endometriosis.

Prof Ford is an experienced university lecturer, convening courses on medical research, cancer pathology and personalised medicine, including Australia's first MOOC (Massive Open Online Course) on Personalised Medicine. She has completed a Graduate Certificate in University Learning & Teaching, and is passionate about science communication and enhancing the health literacy of the wider community. In 2017 she was named as an inaugural ‘ by Science & Technology Australia. In 2018 she received the Women's Agenda Award for Female Leader in Science, Medicine & Health.

Keywords: gynaecological cancer, ovarian cancer, endometrial cancer, endometriosis, metastasis, ascites, early detection, cell-free DNA, Wnt, EMT, ROR1, ROR2, MOOC

Phone

93851451

E-mail

caroline.ford@unsw.edu.au

Location

Adult Cancer Program School of Women's and Children's Health Lowy Cancer Research Centre

Journal articles | 2024

Cortesi M; Liu D; Powell E; Barlow E; Warton K; Ford CE, 2024, 'Accurate Identification of Cancer Cells in Complex Pre-Clinical Models Using a Deep-Learning Neural Network: A Transfection-Free Approach', Advanced Biology,

Journal articles | 2024

Cortesi M; Liu D; Yee C; Marsh DJ; Ford CE, 2024, 'Author Correction: A comparative analysis of 2D and 3D experimental data for the identification of the parameters of computational models (Scientific Reports, (2023), 13, 1, (15769), 10.1038/s41598-023-42486-3)', Scientific Reports, 14,

Journal articles | 2024

Cortesi M; Warton K; Ford CE, 2024, 'Beyond 2D cell cultures: how 3D models are changing the in vitro study of ovarian cancer and how to make the most of them', PeerJ, 12,

Journal articles | 2024

Fisher T; Powell E; Yuwono NL; Ford CE; Warton K, 2024, 'Circulating cell-free DNA is elevated in postmenopausal compared with pre- and perimenopausal women', Menopause, 31, pp. 171 - 175,

Journal articles | 2024

Liu D; Powell E; Wan KM; Athavale R; Loo C; Ford CE, 2024, 'Abstract B014: Patient-derived organoid models for drug screening in molecular subtypes of endometrial cancer', Clinical Cancer Research, 30, pp. B014 - B014,

Journal articles | 2024

Madani DD; Satgunaseelan DL; El-Hayek MJ; Shivalingam PB; Ford PC, 2024, 'ROR1 MRNA EXPRESSION IN GLIOMA - A NOVEL PROGNOSTIC BIOMARKER', Neuro-Oncology, 26, pp. vii4 - vii5,

Journal articles | 2024

Werner B; Powell E; Duggan J; Cortesi M; Lee YC; Arora V; Athavale R; Dean M; Warton K; Ford C, 2024, 'Use of cell-free DNA from ascites to identify variants and tumour evolution in a cohort of patients with advanced ovarian cancer.', Journal of Clinical Oncology, 42, pp. 5547 - 5547,

Journal articles | 2024

Werner B; Powell E; Duggan J; Cortesi M; Lee YC; Arora V; Athavale R; Dean M; Warton K; Ford CE, 2024, 'Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer', Molecular Oncology,

Journal articles | 2024

Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin L; Ananda S; Shannon C; Friedlander M; Warton K; Ford CE, 2024, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial', Translational Oncology, 43,

Journal articles | 2023

Cortesi M; Liu D; Yee C; Marsh DJ; Ford CE, 2023, 'A comparative analysis of 2D and 3D experimental data for the identification of the parameters of computational models', Scientific Reports, 13,

Journal articles | 2023

Phan Z; Ford CE; Caldon CE, 2023, 'DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review', Pharmacological Research, 196,

Journal articles | 2023

Weir A; Kang EY; Meagher NS; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Gentry-Maharaj A; Ryan A; Singh N; Widschwendter M; Alsop J; Anglesio MS; Beckmann MW; Berger J; Bisinotto C; Boros J; Brand AH; Brenton JD; Brooks-Wilson A; Carney ME; Cunningham JM; Cushing-Haugen KL; Cybulski C; Elishaev E; Erber R; Fereday S; Fischer A; Paz-Ares L; Gayarre J; Gilks BC; Grube M; Harnett PR; Harris HR; Hartmann A; Hein A; Hendley J; Hernandez BY; Heublein S; Huang Y; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kommoss FKF; Koziak JM; Kraemer B; Le ND; Lesnock J; Lester J; Lubiński J; Menkiszak J; Ney B; Olawaiye A; Orsulic S; Osorio A; Robles-Díaz L; Ruebner M; Shah M; Sharma R; Shvetsov YB; Steed H; Talhouk A; Taylor SE; Traficante N; Vierkant RA; Wang C; Wilkens LR; Winham SJ; Benitez J; Berchuck A; Bowtell DDL; Candido dos Reis FJ; Cook LS; DeFazio A; DeFazio A; Traficante N; Harnett P; Doherty JA; Fasching PA; García MJ; Goode EL; Goodman MT; Gronwald J; Huntsman DG; Karlan BY; Kommoss S; Modugno F; Schildkraut JM; Sinn HP; Staebler A; Kelemen LE; Ford CE; Menon U; Pharoah PDP; Köbel M; Ramus SJ, 2023, 'Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study', British Journal of Cancer, 128, pp. 137 - 147,

Journal articles | 2023

Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin LR; Ananda S; Shannon CM; Friedlander M; Warton K; Ford C, 2023, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial.', Journal of Clinical Oncology, 41, pp. 5561 - 5561,

Journal articles | 2023

Wong-Brown MWY; Johnson Z; Salem S; Matthews BG; Ford CE; Marsh DJ; Bowden NA, 2023, 'Abstract C041: Drug repurposing to target TGF-β in chemoresistant high-grade serous ovarian cancer', Molecular Cancer Therapeutics, 22, pp. C041 - C041,

Journal articles | 2022

Alonso A; Yuwono NL; Houshdaran S; Abbott J; Rodgers R; Ford CE; Warton K, 2022, 'Comparison of total and endometrial circulating cell-free DNA in women with and without endometriosis', Reproductive BioMedicine Online, 44, pp. 495 - 503,

Journal articles | 2022

Fisher T; Ford CE; Warton K, 2022, 'Recovery Efficiency of Cell-Free DNA After Bisulfite Conversion', Clinical Chemistry, 68, pp. 1219 - 1220,

Journal articles | 2022

Henry CE; Llamosas E; Djordjevic A; Hacker NF; Ford CE, 2022, 'Correction to: Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer (Oncogenesis, (2016), 5, 5, (e226), 10.1038/oncsis.2016.32)', Oncogenesis, 11,

Journal articles | 2022

John M; Ford CE, 2022, 'Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an Alternative Splice Variant of ROR1', Biomedicines, 10, pp. 2559,

Journal articles | 2022

Liu D; Gunther K; Enriquez LA; Daniels B; O’Mara TA; Tang K; Spurdle AB; Ford CE, 2022, 'Author Correction: ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target (Scientific Reports, (2020), 10, 1, (13906), 10.1038/s41598-020-70924-z)', Scientific Reports, 12,

Journal articles | 2022

Liu D; Kaufmann GF; Breitmeyer JB; Dickson KA; Marsh DJ; Ford CE, 2022, 'The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells', Pharmaceutics, 14,

Journal articles | 2022

Madani D; John M; Satgunaseelan L; Shivalingam B; Ford C, 2022, 'BIOM-11. ROR1 MRNA EXPRESSION IN GLIOMA - A NOVEL PROGNOSTIC BIOMARKER', Neuro-Oncology, 24, pp. vii6 - vii6,

Journal articles | 2022

Werner B; Warton K; Ford CE, 2022, 'Endogenous cell-free DNA in fetal bovine serum introduces artifacts to in vitro cell-free DNA models', BioTechniques, 73, pp. 219 - 226,

Journal articles | 2022

Werner B; Warton K; Ford CE, 2022, 'Transcending Blood—Opportunities for Alternate Liquid Biopsies in Oncology', Cancers, 14,

Journal articles | 2022

Xie T; Dickson KA; Yee C; Ma Y; Ford CE; Bowden NA; Marsh DJ, 2022, 'Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival', Cancers, 14,

Journal articles | 2022

Yuwono NL; Alonso A; Abbott J; Houshdaran S; Henry CE; Rodgers R; Ford CE; Warton K, 2022, 'Circulating cell-free endometrial DNA level is unaltered during menstruation and in endometriosis', Human Reproduction, 37, pp. 2560 - 2569,

Journal articles | 2022

Yuwono NL; Boyd MAA; Henry CE; Werner B; Ford CE; Warton K, 2022, 'Circulating cell-free DNA undergoes significant decline in yield after prolonged storage time in both plasma and purified form', Clinical Chemistry and Laboratory Medicine, 60, pp. 1287 - 1298,

Journal articles | 2021

Hagstrom AD; Yuwono N; Warton K; Ford CE, 2021, 'Sex Bias in Cohorts Included in Sports Medicine Research', Sports Medicine, 51, pp. 1799 - 1804,

Journal articles | 2021

Joshi N; Liu D; Dickson KA; Marsh DJ; Ford CE; Stenzel MH, 2021, 'An organotypic model of high-grade serous ovarian cancer to test the anti-metastatic potential of ROR2 targeted Polyion complex nanoparticles', Journal of Materials Chemistry B, 9, pp. 9123 - 9135,

Journal articles | 2021

Liu D; Enriquez L; Ford CE, 2021, 'Ror2 is epigenetically regulated in endometrial cancer', Cancers, 13, pp. 1 - 16,

Journal articles | 2021

Liu D; Sharbeen G; Phillips P; Johns AL; Gill AJ; Chantrill LA; Timpson P; Chou A; Pajic M; Dwarte T; Herrmann D; Vennin C; Cox TR; Pereira B; Ritchie S; Reed DA; Chambers CR; Metcalf X; Nobis M; Waddell N; Pearson JV; Patch AM; Nones K; Newell F; Mukhopadhyay P; Addala V; Kazakoff S; Holmes O; Leonard C; Wood S; Grimmond SM; Hofmann O; Samra JS; Pavlakis N; Arena J; High HA; Asghari R; Merrett ND; Das A; Cosman PH; Ismail K; Stoita A; Williams D; Spigellman A; Lam VW; McLeod D; Kirk J; Kench JG; Grimison P; Sandroussi C; Goodwin A; Mead RS; Tucker K; Andrews L; Texler M; Forrest C; Ballal M; Fletcher D; Beilin M; Feeney K; Epari K; Mukhedkar S; Zeps N; Nguyen NQ; Ruszkiewicz AR; Worthley C; Chen J; Brooke-Smith ME; Papangelis V; Clouston AD; Barbour AP; O’Rourke TJ; Fawcett JW; Slater K; Hatzifotis M; Hodgkinson P; Nikfarjam M; Eshleman JR; Hruban RH; Wolfgang CL; Scarpa A; Lawlor RT; Corbo V; Bassi C; Biankin AV; Jamieson NB; Chang DK; Dreyer SB; Ford CE, 2021, 'ROR1 and ROR2 expression in pancreatic cancer', BMC Cancer, 21,

Journal articles | 2021

Werner B; Yuwono N; Duggan J; Liu D; David C; Srirangan S; Provan P; DeFazio A; Arora V; Farrell R; Lee YC; Warton K; Ford C, 2021, 'Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer', Gynecologic Oncology, 162, pp. 720 - 727,

Journal articles | 2021

Xu X; Wang Y; Bryce NS; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents', British Journal of Cancer, 125, pp. 265 - 276,

Journal articles | 2021

Yuwono NL; Henry CE; Ford CE; Warton K, 2021, 'Total and endothelial cell-derived cell-free DNA in blood plasma does not change during menstruation', PLoS ONE, 16,

Journal articles | 2021

Yuwono NL; Warton K; Ford CE, 2021, 'The influence of biological and lifestyle factors on circulating cell-free dna in blood plasma', eLife, 10,

Journal articles | 2020

Ford CE; Werner B; Hacker NF; Warton K, 2020, 'The untapped potential of ascites in ovarian cancer research and treatment', British Journal of Cancer, 123, pp. 9 - 16,

Journal articles | 2020

Liu D; Gunther K; Enriquez LA; Daniels B; O’Mara TA; Tang K; Spurdle AB; Ford CE, 2020, 'ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target', Scientific Reports, 10,

Journal articles | 2020

Warton K; Xu Y; Ford CE, 2020, 'Target sequence heterogeneity causes the 'hook effect' in fluorescent dye-based quantitative PCR', BioTechniques, 69, pp. 81 - 84,

Journal articles | 2019

Huynh KT; Van Zuylen WJ; Ford CE; Rawlinson WD, 2019, 'Selective modulation of wnt-binding receptor tyrosine kinase ROR2 expression by human cytomegalovirus regulates trophoblast migration', Journal of General Virology, 100, pp. 99 - 104,

Journal articles | 2019

Lu M; Henry CE; Lai H; Khine YY; Ford CE; Stenzel MH, 2019, 'A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles', Biomaterials Science, 7, pp. 1652 - 1660,

Journal articles | 2019

Werner B; Yuwono NL; Henry C; Gunther K; Rapkins RW; Ford CE; Warton K, 2019, 'Circulating cell-free DNA from plasma undergoes less fragmentation during bisulfite treatment than genomic DNA due to low molecular weight', PLoS ONE, 14,

Journal articles | 2018

Coopes A; Henry CE; Llamosas E; Ford CE, 2018, 'An update of Wnt signalling in endometrial cancer and its potential as a therapeutic target', Endocrine-Related Cancer, 25, pp. R647 - R662,

Journal articles | 2018

Cortesi M; Llamosas E; Henry CE; Kumaran RYA; Ng B; Youkhana J; Ford CE, 2018, 'I-AbACUS: A Reliable Software Tool for the Semi-Automatic Analysis of Invasion and Migration Transwell Assays', Scientific Reports, 8,

Journal articles | 2018

Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE, 2018, 'ROR1 and ROR2 play distinct and opposing roles in endometrial cancer', Gynecologic Oncology, 148, pp. 576 - 584,

Journal articles | 2017

Henry C; Hacker N; Ford C, 2017, 'Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis', Oncotarget, 8, pp. 112727 - 112738,

Journal articles | 2017

Henry CE; Emmanuel C; Lambie N; Loo C; Kan B; Kennedy CJ; de Fazio A; Hacker NF; Ford CE, 2017, 'Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer', Translational Oncology, 10, pp. 346 - 356,

Journal articles | 2017

Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2017, 'Validation of specificity of antibodies for immunohistochemistry: the case of ROR2', Virchows Archiv : an international journal of pathology, 470, pp. 99 - 108,

Journal articles | 2017

Warton K; Yuwono NL; Cowley MJ; McCabe MJ; So A; Ford CE, 2017, 'Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma', Molecular Diagnosis and Therapy, 21, pp. 563 - 570,

Journal articles | 2016

Ford CE; Henry C; Llamosas E; Djordjevic A; Hacker N, 2016, 'Wnt signalling in gynaecological cancers: A future target for personalised medicine?', Gynecologic Oncology, 140, pp. 345 - 351,

Journal articles | 2016

Henry C; Llamosas E; Djordjevic A; Hacker N; Ford C, 2016, 'Targeting the RB-E2F pathway in breast cancer', Oncogene, 35, pp. 4829 - 4835,

Journal articles | 2016

Henry C; ford C; hacker N; Djordjevic A; Llamosas E, 2016, 'Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer.', Oncogenesis,

Journal articles | 2016

Hesson LB; Ng B; Zarzour P; Srivastava S; Kwok CT; Packham D; Nunez AC; Beck D; Ryan R; Dower A; Ford CE; Pimanda JE; Sloane MA; Hawkins NJ; Bourke MJ; Wong JWH; Ward RL, 2016, 'Integrated genetic, epigenetic, and transcriptional profiling identifies molecular pathways in the development of laterally spreading tumors', Molecular Cancer Research, 14, pp. 1217 - 1228,

Journal articles | 2016

Ma S; srivastava S; llamosas E; hawkins N; hesson L; ward R; Ford C, 2016, 'ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration.', BMC Cancer, 16, pp. 508,

Journal articles | 2016

Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2016, 'Erratum to: Validation of specificity of antibodies for immunohistochemistry: the case of ROR2 (Virchows Archiv, (2016), 10.1007/s00428-016-2019-5)', Virchows Archiv, 469, pp. 717,

Journal articles | 2016

Naumann F; Yang J-L; Thai T; Ford C; Polly P, 2016, 'Virtual patient consultations and the use of an ePortfolio assessment to support student learning of integrated professional skills', FOCUS ON HEALTH PROFESSIONAL EDUCATION-A MULTIDISCIPLINARY JOURNAL, 17, pp. 69 - 81,

Journal articles | 2016

van Zuylen W; Ford C; Rawlinson W, 2016, 'Comment on: Wnt5a inhibited human trophoblast cell line HTR8/SVneo invasion: implications for early placentation and preeclampsia', The Journal of Maternal-Fetal and Neonatal Medicine,

Journal articles | 2016

van Zuylen WJ; Ford CE; Wong DDY; Rawlinson WD, 2016, 'Human cytomegalovirus modulates expression of noncanonical Wnt receptor ROR2 to alter trophoblast migration', Journal of Virology, 90, pp. 1108 - 1115,

Journal articles | 2016

vanZuylen WJ; Rawlinson WD; Ford C; van Zuijlen W, 2016, 'The Wnt pathway: a key network in cell signalling dysregulated by viruses.', Reviews in Medical Virology, 26, pp. 340 - 355,

Journal articles | 2015

Henry C; Llamosas E; Knipprath-Meszaros A; Schoetzau A; Obermann E; Fuenfschilling M; Caduff R; Fink D; Hacker N; Ward R; Heinzelmann-Schwarz V; Ford C, 2015, 'Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion', Oncotarget, 6, pp. 40310 - 40326,

Journal articles | 2015

Henry C; Quadir A; Hawkins NJ; Jary E; Llamosas E; Kumar D; Daniels B; Ward RL; Ford CE, 2015, 'Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling', Journal of Cancer Research and Clinical Oncology, 141, pp. 243 - 254,

Journal articles | 2015

Henry CE; Knipprath-Meszaros AM; Llamosas E; Schotzau A; Obermann E; Fink D; Hacker N; Ward RL; Heinzelmann-Schwarz V; Ford CE, 2015, 'ROR2 IS A NOVEL TARGET OF THE WNT SIGNALING PATHWAY INVOLVED IN METASTASIS AND CHEMOTHERAPY RESISTANCE', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 25, pp. 476 - 476,

Journal articles | 2014

Ford CE; Punnia-Moorthy G; Henry CE; Llamosas E; Nixdorf S; Olivier J; Caduff R; Ward RL; Heinzelmann-Schwarz V, 2014, 'The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer', Gynecologic Oncology, 134, pp. 338 - 345,

Journal articles | 2013

Ford CE; Jary E; Ma SSQ; Nixdorf S; Heinzelmann-Schwarz VA; Ward RL, 2013, 'The WNT gatekeeper SFRP4 modulates EMT, cell migration and downstream WNT signalling in serous ovarian cancer cells', PLoS ONE, 8, pp. e54362,

Journal articles | 2013

Ford CE; Ma SSQ; Quadir A; Ward RL, 2013, 'The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis', International Journal of Cancer, 133, pp. 779 - 787,

Journal articles | 2013

Loh YN; Hedditch E; Baker L; Jary E; Ward RL; Ford CE, 2013, 'The Wnt signalling pathway is upregulated in acquired Tamoxifen resistant breast cancer.', BMC Cancer, 13, pp. 174,

Journal articles | 2012

Ford CE; Jary E; Ma S; Nixdorf S; Heinzelmann-Schwarz V; Ward RL, 2012, 'SFRP4 modulates EMT, cell migration and downstream Wnt signalling in epithelial ovarian cancer.', CANCER RESEARCH, 72,

Journal articles | 2012

Jacob F; Ukegjini K; Nixdorf S; Ford CE; Olivier J; Caduff R; Scurry J; Guertler R; Hornung D; Mueller R; Fink D; Hacker NF; Heinzelmann-Schwarz VA, 2012, 'Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients', PLoS One, 7, pp. Art no. e31885,

Journal articles | 2011

Ford CE; Ekström EJ; Howlin J; Andersson T, 2011, 'The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERα negative breast cancer (Cell Cycle (2009), 8, (1838-1842))', Cell Cycle, 10, pp. 1167,

Journal articles | 2011

Johal H; Ford CE; Glenn W; Heads J; Lawson JS; Rawlinson WD, 2011, 'Mouse mammary tumor like virus sequences in breast milk from healthy lactating women', Breast Cancer Research and Treatment, 129, pp. 149 - 155,

Journal articles | 2010

Ford CE; Ekström EJ; Andersson T, 2010, 'Erratum: Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells (Proceedings of the National Academy of Sciences of the United Stated of America (2010) 106 (3919-3924) DOI: 10.1073/pnas.0809516106))', Proceedings of the National Academy of Sciences of the United States of America, 107, pp. 22360,

Journal articles | 2009

Ford CE; Ekström EJ; Andersson T, 2009, 'Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells', Proceedings of the National Academy of Sciences of the United States of America, 106, pp. 3919 - 3924,

Journal articles | 2009

Ford CE; Ekström EJ; Howlin J; Andersson T, 2009, 'The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERα negative breast cancer', Cell Cycle, 8, pp. 1838 - 1842,

Journal articles | 2007

Ford CE; Lau S; Zhu CQ; Andersson T; Tsao M; Vogel W, 2007, 'Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma.', British Journal of Cancer, 96, pp. 808 - 814,

Journal articles | 2006

Lawson JS; Tran D; Carpenter E; Ford C; Rawlinson WD; Whitaker NJ; Delprado W, 2006, 'Presence of mouse mammary tumour-like virus gene sequences may be associated with morphology of specific human breast cancer', Journal of Clinical Pathology, 59, pp. 1287 - 1292

Journal articles | 2006

Vogel W; Abdulhussein R; Ford CE, 2006, 'Sensing extracellular matrix: An update on discoidin domain receptor function.', Cellular Signalling, 18, pp. 1108 - 1116

Journal articles | 2005

Faedo M; Ford CE; Rawlinson WD, 2005, 'Contribution by Faedo et al. Response', CLINICAL CANCER RESEARCH, 11, pp. 406 - 406,

Journal articles | 2005

Pogo B; Menard S; Holland JF; Faedo M; Ford CE; Rawlinson WD, 2005, 'Contribution by Faedo et al. (Clin Cancer Res 2004;10:4417-4419) [1]', Clinical Cancer Research, 11, pp. 406

Journal articles | 2004

Faedo M; Ford CE; Mehta R; Blazek K; Rawlinson WD, 2004, 'Mouse mammary tumor like virus is associated with p53 nuclear accumulation and progesterone receptor positivity but not estrogen positivity in human female breast cancer', Clinical Cancer Research, 10, pp. 4417 - 4419

Journal articles | 2004

Ford CE; Faedo M; Delprado W; Rawlinson WD, 2004, 'Correspondence re: C. Ford, et al. Mouse mammary tumor virus-like gene sequences in breast tumors of Australian and Vietnamese women.', Clinical Cancer Research, 10, pp. 802 - 802

Journal articles | 2004

Ford CE; Faedo M; Lawson JS; Rawlinson WD; Crouch R, 2004, 'Progression from normal breast pathology to breast cancer is associated with increasing prevalence of mouse mammary tumor virus-like sequences in men and women.', Cancer research, 64, pp. 4755 - 4759

Journal articles | 2004

Ford CE; Faedo M; Rawlinson WD, 2004, 'Mouse mammary tumor virus-like RNA transcripts and DNA are found inaffected cells of human breast cancer', Clinical Cancer Research, 10, pp. 7284 - 7289

Journal articles | 2004

Lawson JS; Tran D; Ford CE; Rawlinson WD, 2004, 'Elevated expression of the tumor suppressing protein p53 is associated with the presence of mouse mammary tumor-like env gene sequences (MMTV-like) in human breast cancer', Breast Cancer Research and Treatment, 87, pp. 13 - 17

Journal articles | 2003

Ford CE; Tran D; Deng Y; Ta VT; Rawlinson WD; Lawson JS, 2003, 'Mouse mammary tumor virus-like gene sequences in breast tumors of Australian and Vietnamese women', Clinical Cancer Research, 9, pp. 1118 - 1120
Preprints | 2024

Cortesi M; Li J; Liu D; Guo T; Dokos S; Warton K; Ford C, 2024, A novel approach for the quantification of single-cell adhesion dynamics from microscopy images,

Preprints | 2024

Cortesi M; Liu D; Powell E; Barlow E; Warton K; Giordano E; Ford C, 2024, Development and validation of a computational tool to predict treatment outcomes in cells from High-Grade Serous Ovarian Cancer patients,

Preprints | 2024

Werner B; Powell E; Duggan J; Cortesi M; Lee YC; Arora V; Athavale R; Dean M; Warton K; Ford C, 2024, Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer,

Preprints | 2023

Cortesi M; Liu D; Powell E; Barlow E; Warton K; Ford C, 2023, Accurate identification of cancer cells in complex pre-clinical models using deep-learning: a transfection-free approach,

Preprints | 2023

Cortesi M; Liu D; Yee C; Marsh D; Ford C, 2023, Model Parameter identification using 2D vs 3D experimental data: a comparative analysis,

Preprints | 2023

Phan Z; Ford C; Caldon E, 2023, DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: a meta-analysis and systematic review,

Conference Papers | 2023

Werner B; Powell E; Duggan J; Lee YC; Athavale R; Dean M; Warton K; Ford C, 2023, 'PR004/#458 Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in a cohort of patients with advanced ovarian cancer', in Featured Posters: Poster Rounds with the Professors, BMJ Publishing Group Ltd, pp. A32.2 - A33, presented at IGCS 2023 Annual Meeting Abstracts,

Preprints | 2021

John M; Ford C, 2021, Pan-tissue and -cancer analysis of ROR1 and ROR2 transcript variants identify novel functional significance for an alternative splice variant of ROR1,

Preprints | 2021

John M; Rao P; Noor H; Ford C, 2021, ROR1 is a novel putative druggable target for diffuse glioma,

Conference Papers | 2021

Liu D; Enriquez L; Daniels B; O'Mara T; Tang K; Ford C, 2021, 'Abstract PO042: ROR2 is epigenetically regulated in endometrial cancer', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. PO042 - PO042,

Conference Papers | 2021

Liu D; Kaufmann GF; Breitmeyer JB; Dickson K-A; Marsh DJ; Ford CE, 2021, 'Abstract 1062: Inhibition of ovarian and endometrial cancer cell proliferation by an anti-ROR1 monoclonal antibody', in Cancer Research, American Association for Cancer Research (AACR), pp. 1062 - 1062,

Conference Papers | 2021

Liu D; Kaufmann GF; Breitmeyer JB; Dickson K-A; Marsh DJ; Ford CE, 2021, 'Inhibition of ovarian and endometrial cancer cell proliferation by an anti-ROR1 monoclonal antibody.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH,

Conference Papers | 2021

Xu X; Wang Y; Bryce N; Tang K; Meagher NS; Kang EY; Kelemen LE; Kobel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH,

Conference Papers | 2021

Xu X; Wang Y; Bryce N; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Abstract 1045: Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy', in Cancer Research, American Association for Cancer Research (AACR), pp. 1045 - 1045,

Conference Abstracts | 2020

Liu D; Enriquez L; Daniels B; O'Mara T; Tang K; Ford C, 2020, 'ROR2 is epigenetically regulated in endometrial cancer', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 27, presented at AACR Special Conference on Endometrial Cancer - New Biology Driving Research and Treatment, ELECTR NETWORK, 09 November 2020 - 10 November 2020,

Conference Abstracts | 2020

Liu D; Gunther K; Daniels B; O'Mara T; Tang K; Ford C, 2020, 'ROR1: A novel target in endometrial cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 80, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020,

Conference Papers | 2020

Liu D; John M; Henry CE; Christie EL; Bowtell DDL; Tang K; Heinzelmann-Schwarz V; Kennedy C; Boros J; DeFazio A; Ford CE, 2020, 'Abstract A41: ROR1 is associated with ovarian cancer progression and chemoresistance', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. A41 - A41,

Conference Papers | 2020

Warton K; Yuwono N; Henry C; Hacker N; Ford C, 2020, 'Abstract B28: Optimizing DNA processing and ovarian cancer methylation-specific PCR assays for the detection of early-stage ovarian cancer', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. B28 - B28,

Conference Abstracts | 2020

Yuwono NL; Warton K; Henry C; Ford C, 2020, 'Deciphering the origin of circulating cell-free DNA and its alterations during menstruation', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 80, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020,

Conference Abstracts | 2019

Liu D; John M; Henry CE; Christie EL; Bowtell DDL; Tang K; Heinzelmann-Schwarz V; Kennedy C; Boros J; DeFazio A; Ford CE, 2019, 'ROR1 is associated with ovarian cancer progression and chemoresistance.', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 26, pp. 59 - 60, presented at AACR Special Conference on Advances in Ovarian Cancer Research, GA, Atlanta, 13 September 2019 - 16 September 2019,

Conference Papers | 2019

Warton K; Yuwono N; Henry C; Hacker N; Ford C, 2019, 'Optimizing DNA processing and ovarian cancer methylation-specific PCR assays for the detection of early-stage ovarian cancer.', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, pp. 93 - 93, presented at AACR Special Conference on Advances in Ovarian Cancer Research, GA, Atlanta, 13 September 2019 - 16 September 2019,

Conference Papers | 2018

Henry CE; Hacker NF; Ford CE, 2018, 'Shock and ROR! Targeting ROR1 and ROR2 in a preclinical patient-derived model of ovarian cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018,

Conference Posters | 2016

Chisholm OT; Gomes L; Thai T; Nixdorf S; Williams R; Clayphan A; Vigentini L; Zhang C; Zhao L; King M; Ford C, (ed.), 2016, 'Empowering Online Learners Using Assessment and Feedback', UNSW, presented at Towards 2025: Inspiring Learning, UNSW, 31 October 2016 - 31 October 2016

Conference Presentations | 2016

Ford C; Chisholm O; Gomes L, 2016, 'The Hope and Hype of the Genetic Revolution: Reflections on UNSW Medicine's First MOOC', presented at Connections Seminar Series, UNSW Australia, UNSW Australia, 19 May 2016 - 19 May 2016

Conference Papers | 2016

Henry CE; Llamosas E; Hacker NF; Heinzelmann-Schwarz V; Ford CE, 2016, 'The role of the ROR receptors in ovarian cancer progression and chemoresistance', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at 107th Annual Meeting of the American-Association-of-Cancer-Research (AACR), LA, New Orleans, 16 April 2016 - 20 April 2016,

Conference Presentations | 2016

Nixdorf S; Chisholm OT; Gomes L; Ford C, 2016, 'Student Engagement in the Personalised Medicine MOOC: Does the Learning Platform Matter?', presented at UNSW Medicine Learning and Teaching Forum, UNSW, Sydney, 07 December 2016 - 07 December 2016

Conference Presentations | 2015

Ford C; Chisholm OT; Gomes L, 2015, 'Hope and Hype: Reflections on UNSW Medicine's First MOOC', presented at 2015 UNSW Medicine Learning and Teaching Forum, UNSW, Sydney, NSW, Australia, 02 December 2015 - 02 December 2015,

Conference Presentations | 2014

Chisholm O; Nixdorf S; Williams R; Ford C, 2014, 'Reflections on the development of an open online course', presented at UNSW Medicine Learning and Teaching Forum 2014, UNSW Australia, 10 December 2014 - 10 December 2014,

Conference Presentations | 2014

Ford C, 2014, 'Hear the Ror! The role of Wnt signalling in ovarian cancer.', presented at International Society for Gynecologic Cancers, Melbourne, 08 November 2014 - 11 April 2015

Conference Presentations | 2014

Ford CE; Henry CE; Llamosas E; Djordjevic A; Hacker NF; Heinzelmann-Schwarz VA; Ward RL, 2014, 'HEAR THE ROR! THE ROLE OF WNT SIGNALLING IN OVARIAN CANCER'

Conference Papers | 2010

Ford CE; Tuomela J; Hedditch EL; Axelsson L; Liu Q; Ward RL; Harkonen P; Andersson T, 2010, 'Estrogen receptor alpha is upregulated and metastasis inhibited in a murine breast cancer model following treatment with the novel Wnt-5a derived-hexapeptide, Foxy-5', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, NORWAY, Oslo, pp. 11 - 11, presented at 21st Meeting of the European-Association-for-Cancer-Research, NORWAY, Oslo, 26 June 2010 - 29 June 2010,

Conference Papers | 2005

Kennedy S; Waliuzzaman Z; Ford C; Rawlinson W; Pussell B, 2005, 'Recurrent HUS following kidney transplant possibly precipitated by CMV', in IMMUNOLOGY AND CELL BIOLOGY, BLACKWELL PUBLISHING, AUSTRALIA, Canberra, pp. A16 - A17, presented at 23rd Annual Scientific Meeting of the Transplantation-Society-of-Australia-and-New-Zealand, AUSTRALIA, Canberra, 11 May 2005 - 13 May 2005,

Media | 2015

Ford C; Chisholm O, 2015, Brace yourself genetic testing might give you more than you bargained for.,

Looking for another way to support the development of an early detection test for ovarian cancer? Please consider donating your blood for research. A/Prof Ford’s team needs large numbers of blood donations from diverse women to assist in the development of their test. If you are >18 and located in Sydney please contact earlydetection@unsw.edu.au for more information.

Founder,

Chair, ANZGOG Uterine Tumour Type Working Group

Research Chair, Cure Cancer Australia

with author Angela Saini

My Research Supervision

Primary supervision:

PhD student Kate Gunther
PhD student Bonnie Werner

Co-supervision

PhD student Zoe Phan (Primary supervisor A/Prof Liz Caldon)

My Teaching

Dr Ford developed and currently convenes the UNSW General Education course, Personalised Medicine (GENM0295).

Dr Ford developed and convened the Myths and Realities of Personalised Medicine MOOC (Massive Open Online Course) previously offered on the Coursera and Future Learn platforms in 2016 and 2017.

51�Թ�app

Follow

Professor Caroline Ford

Follow me